Crespo-Trevino Ricaurte, Schiffman Jade, Ugradar Shoaib, Cockerham Kimberly, Douglas Raymond, de Leon-Garza David, Tang Rosa
Universidad de Monterrey, Monterrey, Mexico.
Neuro-Ophthalmology of Texas, and Neuro-Eye Clinical Trials Inc., Houston, Texas, USA.
Endocrinol Diabetes Metab Case Rep. 2022 Mar 1;2022. doi: 10.1530/EDM-21-0201.
Thyroid dermopathy is an uncommon manifestation of thyroid disease that impairs the quality of life in certain cases. Currently, the available treatments offer limited results and a chance of recurrence. Teprotumumab, a novel medication that results in the regression of thyroid ophthalmopathy, may have similar effects on dermopathy. We describe four patients treated with teprotumumab for their thyroid ophthalmopathy who concomitantly had dermatopathy upon initiation of their infusions. Patients improved after two to three infusions and three out of the four patients have not suffered a recurrence.Teprotumumab is a monoclonal antibody (MAB) that attenuates an inflammatory response, resulting in decreased edema and tissue expansion. Given the similarities of their pathophysiology, we believe that the resolution of thyroid dermatopathy and regression of thyroid eye disease occurs via the same mechanism. We encourage further investigation utilizing teprotumumab for patients whose dermopathy is associated with impaired quality of life.
Thyroid dermopathy (TD), an uncommon manifestation of thyroid disease, may occasionally impair function and quality of life. There are only a few treatments for TD, with limited results and high rates of recurrence. Teprotumumab is a Food and Drug Administration-approved medication used for thyroid eye disease (TED). Our patients treated with teprotumumab for TED showed improvement of TD, which demonstrates its potential use for this condition.
甲状腺皮肤病变是甲状腺疾病的一种罕见表现，在某些情况下会损害生活质量。目前，现有的治疗方法效果有限且有复发的可能。替普罗单抗是一种可使甲状腺眼病消退的新型药物，可能对皮肤病变有类似作用。我们描述了4例因甲状腺眼病接受替普罗单抗治疗的患者，在开始输注时同时患有皮肤病变。2至3次输注后患者病情改善，4例患者中有3例未复发。替普罗单抗是一种单克隆抗体（MAB），可减轻炎症反应，从而减少水肿和组织扩张。鉴于其病理生理学的相似性，我们认为甲状腺皮肤病变的消退和甲状腺眼病的缓解是通过相同机制发生的。我们鼓励对皮肤病变影响生活质量的患者进一步开展使用替普罗单抗的研究。
甲状腺皮肤病变（TD）是甲状腺疾病的一种罕见表现，偶尔会影响功能和生活质量。TD的治疗方法很少，效果有限且复发率高。替普罗单抗是一种经美国食品药品监督管理局批准用于治疗甲状腺眼病（TED）的药物。我们用替普罗单抗治疗TED的患者TD有所改善，这表明其在这种情况下的潜在用途。
